Ali Saber

785 total citations
34 papers, 506 citations indexed

About

Ali Saber is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ali Saber has authored 34 papers receiving a total of 506 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 14 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ali Saber's work include Lung Cancer Treatments and Mutations (11 papers), Cancer-related molecular mechanisms research (9 papers) and Lung Cancer Research Studies (6 papers). Ali Saber is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer-related molecular mechanisms research (9 papers) and Lung Cancer Research Studies (6 papers). Ali Saber collaborates with scholars based in Netherlands, Iran and China. Ali Saber's co-authors include Hidde J. Haisma, Bin Liu, Anke van den Berg, T. Jeroen N. Hiltermann, Harry J.M. Groen, Klaas Kok, Anthonie J. van der Wekken, Ali Rajabi, Wim Timens and Ed Schuuring and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Ali Saber

30 papers receiving 486 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ali Saber Netherlands 14 269 205 170 148 52 34 506
Raquel Bermudo Spain 10 254 0.9× 121 0.6× 169 1.0× 131 0.9× 29 0.6× 13 425
Caterina Aversa Italy 12 210 0.8× 285 1.4× 222 1.3× 108 0.7× 24 0.5× 32 553
Carla Azzurra Amoreo Italy 15 249 0.9× 193 0.9× 75 0.4× 148 1.0× 32 0.6× 25 492
Prabhjot S. Mundi United States 9 290 1.1× 175 0.9× 111 0.7× 92 0.6× 24 0.5× 27 490
Marianna Sirico Italy 12 172 0.6× 199 1.0× 125 0.7× 129 0.9× 15 0.3× 34 406
Arpita Desai United States 10 229 0.9× 165 0.8× 185 1.1× 116 0.8× 17 0.3× 38 451
Shengguang Yuan China 15 469 1.7× 231 1.1× 101 0.6× 259 1.8× 88 1.7× 21 728
Yao-Chen Wang Taiwan 11 345 1.3× 152 0.7× 75 0.4× 136 0.9× 33 0.6× 13 489
M Paesmans Belgium 5 159 0.6× 225 1.1× 196 1.2× 75 0.5× 52 1.0× 6 455
Shuiping Gao China 13 263 1.0× 229 1.1× 99 0.6× 194 1.3× 25 0.5× 28 539

Countries citing papers authored by Ali Saber

Since Specialization
Citations

This map shows the geographic impact of Ali Saber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Saber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Saber more than expected).

Fields of papers citing papers by Ali Saber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Saber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Saber. The network helps show where Ali Saber may publish in the future.

Co-authorship network of co-authors of Ali Saber

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Saber. A scholar is included among the top collaborators of Ali Saber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Saber. Ali Saber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rajabi, Ali, Reza Safaralizadeh, Ali Saber, et al.. (2024). Apoptotic effect of melatonin on ER-positive breast cancer cell lines: ADGRL4 gene expression and promoter methylation. Naunyn-Schmiedeberg s Archives of Pharmacology. 398(2). 1815–1823.
2.
Rajabi, Ali, Ali Saber, Joost Kluiver, et al.. (2024). NEAT1 and CHROMR lncRNAs: a promising diagnostic tool for diffuse large B-cell lymphoma especially in elderly patients. Biomarkers in Medicine. 18(15-16). 685–693.
3.
Zhang, Xu, Ali Saber, Min Wei, et al.. (2023). Development and validation of a nomogram model for lung cancer based on radiomics artificial intelligence score and clinical blood test data. Frontiers in Oncology. 13. 1132514–1132514. 6 indexed citations
4.
5.
Rajabi, Ali, et al.. (2021). Moderate Prognostic Value of lncRNA FOXD2-AS1 in Gastric Cancer with Helicobacter pylori Infection. Journal of Gastrointestinal Cancer. 53(3). 687–691. 16 indexed citations
6.
Gavgani, Reyhaneh Ravanbakhsh, et al.. (2021). Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: A review of the literature. Biomedicine & Pharmacotherapy. 143. 112190–112190. 36 indexed citations
7.
Rajabi, Ali, et al.. (2021). Prognostic Value of LncRNA KRT18P55 in Patients with Intestinal Type of Gastric Cancer. Journal of Gastrointestinal Cancer. 53(4). 1014–1019. 10 indexed citations
8.
Saber, Ali, et al.. (2021). Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells. Current Stem Cell Research & Therapy. 16(7). 877–887. 5 indexed citations
9.
Rybczynska, Anna A., Martijn Terpstra, Ali Saber, et al.. (2020). An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients. Cancers. 12(10). 2843–2843. 9 indexed citations
10.
Liu, Bin, Deng Chen, Shipeng Chen, Ali Saber, & Hidde J. Haisma. (2020). Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer. Biochemical Pharmacology. 178. 114095–114095. 16 indexed citations
11.
Liu, Bin, Shanshan Song, Rita Setroikromo, et al.. (2019). CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor. Cancers. 11(4). 455–455. 16 indexed citations
12.
Liu, Bin, Ali Saber, & Hidde J. Haisma. (2019). CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discovery Today. 24(4). 955–970. 58 indexed citations
13.
Saber, Ali, et al.. (2019). CRISPR/Cas9 for overcoming drug resistance in solid tumors. DARU Journal of Pharmaceutical Sciences. 28(1). 295–304. 29 indexed citations
14.
Wekken, Anthonie J. van der, JG Kuiper, Ali Saber, et al.. (2017). Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. PLoS ONE. 12(8). e0182885–e0182885. 19 indexed citations
15.
Saber, Ali, Anthonie J. van der Wekken, Klaas Kok, et al.. (2016). Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. PLoS ONE. 11(4). e0153065–e0153065. 13 indexed citations
16.
Wekken, Anthonie J. van der, Ali Saber, T. Jeroen N. Hiltermann, et al.. (2016). Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. Critical Reviews in Oncology/Hematology. 100. 107–116. 86 indexed citations
17.
Saber, Ali, Anthonie J. van der Wekken, Maarten van den Berge, et al.. (2016). Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer. PLoS ONE. 11(3). e0152317–e0152317. 9 indexed citations
18.
Saber, Ali, T. Jeroen N. Hiltermann, Klaas Kok, et al.. (2016). Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors. Carcinogenesis. 38(2). bgw128–bgw128. 28 indexed citations
19.
Saber, Ali, Anthonie J. van der Wekken, T. Jeroen N. Hiltermann, et al.. (2015). Genomic aberrations guiding treatment of non-small cell lung cancer patients. University of Groningen research database (University of Groningen / Centre for Information Technology). 4. 23–33. 19 indexed citations
20.
Hokkam, Emad, et al.. (2012). Laparoscopic elective cholecystectomy with and without drain: A controlled randomised trial. Journal of Minimal Access Surgery. 8(3). 90–90. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raquel Bermudo Breakdown of academic impact, for papers by Caterina Aversa Breakdown of academic impact, for papers by Carla Azzurra Amoreo Breakdown of academic impact, for papers by Prabhjot S. Mundi Breakdown of academic impact, for papers by Marianna Sirico Breakdown of academic impact, for papers by Arpita Desai Breakdown of academic impact, for papers by Shengguang Yuan Breakdown of academic impact, for papers by Yao-Chen Wang Breakdown of academic impact, for papers by M Paesmans Breakdown of academic impact, for papers by Shuiping Gao
Rankless by CCL
2026